Vistagen to Present at Stifel 2022 Healthcare Conference
November 03 2022 - 8:30AM
Business Wire
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the
Company), a late clinical-stage biopharmaceutical company aiming to
transform the treatment landscape for individuals living with
anxiety, depression and other central nervous system (CNS)
disorders, today announced that its Chief Executive Officer, Shawn
Singh, will present and host one-on-one meetings at the Stifel 2022
Healthcare Conference taking place in New York on November 15 and
16, 2022.
Stifel 2022 Healthcare Conference Details Presentation
Date and Time: Tuesday, November 15, 2022 at 9:10 a.m. Eastern Time
Location: New York, New York
Investors interested in arranging a one-on-one meeting during
the conference should contact the Stifel 2022 Healthcare Conference
coordinator.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused
biopharmaceutical company striving to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. The Company is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those that are currently available.
Vistagen’s clinical-stage candidates are targeting multiple forms
of anxiety and depression. PH94B and PH10 belong to a new class of
drugs known as pherines, which are investigational neuroactive
steroids designed with a novel rapid-onset mechanism of action that
activates chemosensory neurons in the nasal passages and can impact
the olfactory-amygdala neural circuits without systemic uptake or
direct activity on CNS neurons in the brain. Vistagen is passionate
about transforming mental health care and redefining what is
possible in the treatment of anxiety and depression – one mind at a
time. Connect at www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221103005640/en/
Investors: Mark Flather Vice President, Investor
Relations (650) 577-3617 mflather@vistagen.com
Media: Nate Hitchings SKDK nhitchings@skdknick.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
